We are pleased and excited to welcome you to the first issue of Retina Today for 2008.

You will quickly notice that the editors are diligently working to incorporate many new features, sections, departments, and columns in the publication that we are sure will capture your interest. We kick off the year with a special focus on combination therapy for neovascular age-related macular degeneration (AMD). Clearly this topic is of significant interest to retina specialists and presents a potential paradigm shift in the way we treat and manage patients with AMD. Albert Augustin has played a seminal role in the inception of combination therapy; he along with his colleagues discuss some of the latest thinking in this arena. Other articles by Mark Hughes and Delia Sang; Henry Hudson; Frank Koch and Robert Josephberg; and Peter Kaiser round out this important topic area.

The new columns and columnists we have added to the lineup include Retina Pearls (Section Editors, Dean Eliott and Ingrid Scott); ASCs: What You Really Need to Know (Section Editor, Pravin Dugel); Ventures in Translation (Section Editor, Elias Reichel); and Medical Update (Section Editor, David Boyer).

To highlight and emphasize the international reach and distribution of Retina Today, Albert Augustin and Stanislao Rizzo coordinate the Global Perspectives column. You will also find a column by retina fellows in each issue focusing on topics of particular interest to those in training; Omesh Gupta and Anita Prasad are leading this effort. The first installment is a two-part article that examines the job search and interviewing—timely topics for all fellows.

Other important areas of interest covered in this issue include an update on the treatment of retinoblastoma from Carol Shields, new PPV codes by Mitchell Fineman, and news with regard to Avastin availability. This issue's signature 5Q feature is an intriguing interview with Steve Charles.

Retina Today will strive to bring you clinical and practice insights from the leaders in our field, provide a forum for lively discussion and perhaps a dose of controversy, as well as provide a place to find expanded medical, news, and industry information.

As always, we welcome and encourage your feedback and suggestions on ways to make Retina Today even more relevant and helpful to you, your practice, and the care of your patients.